Skip to main content

Table 2 Markers of liver injury or fibrosis by viral hepatitis co-infection status

From: HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study

  HIV
Mono-infection
HIV/HCV
Co-infection
HIV/HBV
Co-infection
HIV/HCV/HBV
Co-infection
Total
  n (%) or median [IQR]
ALT      
 Number with measurement available 514 231 91 63 899
 Measure above 19 U/L 269 (52.3) 195 (84.4) 60 (65.9) 52 (82.5) 576 (64.1)
 Measure above 41 U/L 64 (12.5) 122 (52.8) 18 (19.8) 11 (17.5) 215 (23.9)
DAIDS grading (ULN taken as 41 U/L)      
  Grade 1, mild 33 (6.4) 72 (31.2) 9 (9.9) 10 (15.9) 124 (13.8)
  Grade 2, moderate 3 (0.6) 21 (9.1) 0 0 24 (2.7)
  Grade 3 or 4, severe /potentially life threatening 0 7 (3.0) 0 0 7 (0.8)
AST      
 Number with measurement available 514 231 91 63 899
 Measure above ULN of 38 U/L 127 (24.7) 141 (61.0) 18 (19.8) 18 (28.6) 304 (33.8)
 DAIDS grading (ULN 38 U/L)      
  Grade 1, mild 81 (15.8) 86 (37.2) 12 (13.2) 7 (11.1) 186 (20.7)
  Grade 2, moderate 2 (0.4) 25 (10.8) 0 4 (6.4) 31 (3.5)
  Grade 3 or 4, severe /potentially life threatening 1 (0.2) 4 (1.7) 0 0 5 (0.6)
APRI score      
 Number with measure available 445 171 86 60 762
 Median APRI [IQR] 0.27 [0.17, 0.42] 0.55 [0.30, 0.92] 0.23 [0.17, 0.34] 0.30 [0.21, 0.43] 0.30 [0.18, 0.52]
  < 0.5 (no significant fibrosis) 358 (80.5) 81 (47.4) 74 (86.1) 48 (80.0) 561 (73.6)
 0.5- ≤ 1.5 (intermediate) 76 (17.1) 69 (40.4) 12 (14.0) 10 (16.7) 167 (21.9)
  > 1.5 (significant fibrosis) 11 (2.5) 21 (12.3) 0 2 (3.3) 34 (4.5)
FIB-4      
 Number with measure available 444 171 86 60 761
 Median FIB-4 [IQR] 0.61 [0.39, 0.93] 0.88 [0.59, 1.47] 0.53 [0.36, 0.74] 0.68 [0.50, 0.90] 0.67 [0.42, 1.01]
  < 1.45 (no advanced fibrosis) 403 (90.8) 128 (74.9) 85 (98.8) 53 (88.3) 669 (87.9)
 1.45-3.25 (intermediate) 37 (8.3) 41 (24.0) 1 (1.2) 4 (6.7) 83 (10.9)
  > 3.25 (advanced fibrosis) 4 (0.9) 2 (1.2) 0 3 (5.0) 9 (1.2)